Shanghai Universal Biotech Co., Ltd. Class A

Shanghai Universal Biotech Co., Ltd. Class A

SSZSE:301166
27.24
CNY
-0.70
(-2.51%)
-0.18EPS
3.05BMarket Cap
Apr 27Next Earn

Total Valuation

CNY

As of September 30, 2026, Shanghai Universal Biotech Co., Ltd. Class A carries a market capitalization of 3.05B, placing it among publicly traded companies globally. Its enterprise value stands at 2.07B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.05B
Enterprise Value2.07B

Important Dates

Shanghai Universal Biotech Co., Ltd. Class A's next confirmed earnings release is scheduled for April 27, 2027.

Earnings Date4/27/2027

Share Statistics

As of September 30, 2026, Shanghai Universal Biotech Co., Ltd. Class A has 86.17M shares outstanding.

Shares Outstanding86.17M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 2.46, and the price-to-book ratio stands at 1.56.

PS Ratio2.46
PB Ratio1.56
P/TBV Ratio1.57

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 1.69 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.07B versus a market cap of 3.05B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.69

Financial Position

As of September 30, 2026, Shanghai Universal Biotech Co., Ltd. Class A maintains a current ratio of 5.26, meaning it holds 5.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.50, indicating elevated leverage, while an interest coverage ratio of -79.22 demonstrates limited ability to service its debt obligations.

Current Ratio5.26
Quick Ratio3.23
Debt / Equity4.50
Debt / EBITDA-2.76
Interest Coverage-79.22

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Shanghai Universal Biotech Co., Ltd. Class A posted a negative return on equity (ROE) of -0.78, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -0.69, reflecting losses generated across the asset base. The company generates approximately 1.51M in revenue per employee across its workforce of 810.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 6.78 indicates how many times Shanghai Universal Biotech Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-0.78
Return on Assets (ROA)-0.69
Revenue Per Employee1.51M
Employee Count810.00
Inventory Turnover6.78

Taxes

CNY

Over the twelve months ended September 30, 2026, Shanghai Universal Biotech Co., Ltd. Class A recorded an income tax benefit of -16.44M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -31.94M and -15.49M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-16.44M

Stock Price Statistics

CNY

As of the close on November 17, 2026, Shanghai Universal Biotech Co., Ltd. Class A's stock has declined approximately 18.69% over the past 52 weeks. The 50-day moving average sits at 30.32, while the 200-day moving average is 29.88.

52-Week Price Change-18.69%
50-Day Moving Average30.32
200-Day Moving Average29.88

Income Statement

CNY

Over the twelve months ended September 30, 2026, Shanghai Universal Biotech Co., Ltd. Class A generated 1.22B in revenue and converted that into -15.49M in net income, yielding earnings per share of -0.18. EBITDA reached -31.82M, while operating income came in at -38.79M.

Revenue1.22B
Gross Profit247.69M
Operating Income-38.79M
Pretax Income-31.94M
Net Income-15.49M
EBITDA-31.82M
EBIT-31.82M
Earnings Per Share (EPS)-0.18

Balance Sheet

CNY

As of September 30, 2026, Shanghai Universal Biotech Co., Ltd. Class A holds 1.07B in cash and equivalents against 87.68M in total debt, resulting in a net debt position of -177.14M. Total book value stands at 1.95B, with working capital of 1.41B providing operational flexibility.

Cash & Cash Equivalents1.07B
Total Debt87.68M
Net Debt-177.14M
Equity (Book Value)1.95B
Book Value Per Share22.62
Working Capital1.41B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-79.40M

Margins

Over the twelve months ended September 30, 2026, Shanghai Universal Biotech Co., Ltd. Class A posted a gross margin of 20.25, reflecting its pricing power and cost economics. The operating margin of -3.17 and net profit margin of -1.27 provide insight into operational efficiency.

Gross Margin20.25
Operating Margin-3.17
Pretax Margin-2.61
Profit Margin-1.27
EBITDA Margin-2.60

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Shanghai Universal Biotech Co., Ltd. Class A paid dividends of 0.02 per share. The dividend payout ratio of -8.58 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -0.20, meaning Shanghai Universal Biotech Co., Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Dividend Per Share0.02
Payout Ratio-8.58
Shareholder Yield-0.20

Scores

As of September 30, 2026, Shanghai Universal Biotech Co., Ltd. Class A has an Altman Z-Score of 6.59, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score6.59